|
- AstraZeneca | Cafepharma
After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a particular type of breast cancer, the companies have scored an FDA approval in the indication
- AstraZeneca | Cafepharma
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns over clotting complications – including deaths – in people taking the drug
- baxdrostat | Cafepharma
AstraZeneca's baxdrostat has hit the mark in another phase 3 trial involving people who struggle to control their blood pressure with current therapies, keeping the would-be blockbuster on track for regulatory filings this year
- Imfinzi | Cafepharma
The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial With its practice-changing regimen, Imfinzi is the first immunotherapy approved for neoadjuvant treatment, as it is administered in combination with chemotherapy in this setting and postoperatively as
- Caprelsa | Cafepharma
Caprelsa AstraZeneca sells rare cancer drug to Sanofi for up to $300 million Submitted by admin on Mon, 07 27 2015 - 10:00 Read more about AstraZeneca sells rare cancer drug to Sanofi for up to $300 million Source Yahoo Reuters Headline
- light chain amyloidosis | Cafepharma
Almost four years after penning its first amyloidosis collaboration with Neurimmune, AstraZeneca has returned to pick up a second asset The latest licensing deal involves NI009, a preclinical monoclonal antibody that targets lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis
- AstraZeneca | Cafepharma Message Boards | Pharma Sales, Device Sales . . .
Anonymous board for AstraZeneca Happy Holidays from Cafepharma! To allow its staff to spend holiday time with their families, the Cafepharma Message Boards will be switched to read-only from 4:00 PM ET on Wednesday, December 24 until 10:00 PM ET on Thursday, December 25 During this time, all posts will be available for view However, no one will be able to make new posts during this time
- Airsupra | Cafepharma
AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients AstraZeneca Direct will go live October 1, the drugmaker announced Friday, giving eligible patients a new way to order Farxiga, Airsupra and FluMist directly to their homes
|
|
|